Answers are grounded in this paper and cite their sources.
Background Anastomotic leakage (AL) remains the most devastating complication after laparoscopic gastrointestinal surgery. Intraoperative chromogenic agents—defined as substances administered during surgery to provide real time, visually interpretable or fluorescence based feedback on tissue perfusion and/or anastomotic mechanical integrity—have become integral tools for anastomotic assessment. This definition encompasses conventional dyes (e.g., methylene blue, indigo carmine), near infrared fluorescence agents [e.g., indocyanine green (ICG)], and novel targeted and activatable fluorophores. While dye free optical modalities such as hyperspectral imaging and laser speckle contrast imaging represent a technological extension of this concept, they are discussed for comparative and contextual purposes. This review comprehensively examines the current evidence for both established and emerging intraoperative chromogenic agents. Main body ICG fluorescence angiography is supported by multiple meta analyses demonstrating statistically significant reductions in AL with pooled odds ratios of 0.27–0.29, although the PILLAR III randomized trial ( n = 347), terminated early because of slow accrual, did not achieve statistical significance for its primary endpoint (AL rate 7.6% vs. 9.6%, p = 0.37). Novel quantitative approaches—including fluorescence time curve analysis, normalized perfusion indices, and artificial intelligence assisted interpretation—reduce the subjectivity inherent in visual ICG assessment. The “dual assessment” strategy, combining pre anastomotic ICG perfusion mapping with post-anastomotic methylene blue leak testing, is gaining acceptance as a comprehensive evaluation protocol. Beyond ICG, several novel chromogenic agents have entered clinical investigation: (1) MB 102, a novel renal-clearable fluorescent agent enabling repeated perfusion assessments without hepatic washout concerns; (2) ZW800 1, a zwitterionic near infrared fluorophore providing superior signal to background ratio compared to ICG; (3) IRDye® 800CW, a targeted molecular probe conjugatable to antibodies for tissue specific imaging; (4) ONM 100, a pH activatable fluorescent agent that selectively illuminates acidic microenvironments associated with ischemia; and (5) LUM015, a protease activated imaging agent that fluoresces in the presence of cathepsin proteases upregulated during tissue injury. Emerging dye-free optical technologies—hyperspectral imaging and laser speckle contrast imaging—are also expanding the concept of “chromogenic assessment.” Conclusions The field of intraoperative chromogenic agents is rapidly evolving from simple dye based leak testing to sophisticated quantitative perfusion imaging and molecularly targeted visualization. While ICG remains the current reference standard, novel agents and integrated multimodal imaging platforms promise to further improve anastomotic safety. The next decade will likely see regulatory approval and clinical adoption of several of these emerging technologies, contingent upon the successful completion of adequately powered Phase III trials.
No takes yet. Share an insight, caveat, or question.
Qiaoyun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: